Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

Am J Hematol. 2018 Oct;93(10):E342-E345. doi: 10.1002/ajh.25232. Epub 2018 Aug 31.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthropometry
  • Antineoplastic Agents / adverse effects*
  • Dasatinib / adverse effects
  • Glucose Intolerance / chemically induced*
  • Glucose Intolerance / physiopathology
  • Humans
  • Hyperinsulinism / chemically induced
  • Hyperinsulinism / physiopathology
  • Imatinib Mesylate / adverse effects
  • Insulin / blood
  • Insulin Resistance*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Male
  • Prospective Studies
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrimidines / adverse effects*

Substances

  • Antineoplastic Agents
  • Insulin
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • nilotinib
  • Dasatinib